RxDoctor Payments Data

John Stewart, MD

Family Medicine · Alhambra, CANPI 1417031022

Payments from drug & device makers

$7,041in general payments, 2019–2025

Across 350 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$847
  • Lilly USA, LLC$811
  • Bayer$656
  • GSK$579
  • Novo Nordisk$319
  • Almatica Pharma LLC$286
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$6,98099%
  • Education$20%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,041 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$102,146
Medicare patients
259
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone84$83,435
JanuviaSitagliptin Phosphate57$61,746
OzempicSemaglutide53$57,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$44,854
FarxigaDapagliflozin Propanediol39$44,723
MounjaroTirzepatide32$29,915
RybelsusSemaglutide19$29,912
XareltoRivaroxaban20$27,042
TrulicityDulaglutide16$25,855
JardianceEmpagliflozin19$22,287
TradjentaLinagliptin31$22,228
GemtesaVibegron18$19,510
EliquisApixaban16$17,779
JanumetSitagliptin Phos/Metformin Hcl15$14,643
EntrestoSacubitril/Valsartan22$14,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$319$87,34972 claims
BayerKerendia$656$83,43584 claims
MerckJanuvia, Janumet$186$76,38972 claims
Lilly USA, LLCMounjaro, Trulicity$811$55,77048 claims
GSKTrelegy Ellipta, Breo Ellipta$579$55,31384 claims
AstraZenecaFarxiga$184$44,72339 claims
Boehringer IngelheimJardiance, Tradjenta$270$44,51550 claims
Johnson & JohnsonXarelto$54$27,04220 claims
Sumitomo Pharma America, Inc.Gemtesa$192$19,51018 claims
PfizerEliquis$144$17,77916 claims
NovartisEntresto$177$14,08022 claims
AbbVieSynthroid$847$1,94823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →